4.6 Review

The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/ IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies

Journal

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 169, Issue -, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2021.103567

Keywords

Molecular profiling; Molecular tumor board; Mutational oncology; Precision oncology

Ask authors/readers for more resources

The development of innovative technologies and advances in genetics and genomics have provided new opportunities for personalized treatment in oncology. However, this approach is challenging and requires collaboration among different specialists to ensure access and economic sustainability of required genomic tests. This position paper by Italian scientific societies critically discusses the technologies, criteria for patient selection, sample selection and analysis, and regulatory and pharmaco-economic issues.
The development of innovative technologies and the advances in the genetics and genomics, have offered new opportunities for personalized treatment in oncology. Although the selection of the patient based on the molecular characteristics of the neoplasm has the potential to revolutionize the therapeutic scenario of oncology, this approach is extremely challenging. The access, homogeneity, and economic sustainability of the required genomic tests should be warranted in the clinical practice, as well as the specific scientific and clinical expertise for the choice of medical therapies. All these elements make essential the collaboration of different specialists within the Molecular Tumor Boards (MTBs). In this position paper, based on experts' opinion, the AIOM-SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies critically discuss the available molecular profiling technologies, the proposed criteria for the selection of patients candidate for evaluation by the MTB, the criteria for the selection and analysis of biological samples, and the regulatory and pharmaco-economic issues.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available